Ignacio Anegon

USPTO Granted Patents = 9 (Patent Applications = 10)

CIPO Patents = 1 (Patent Applications = 6)

EPO Patents = 8 (Patent Applications = 19)

Average Co-Inventor Count = 2.8

ph-index = 1

Forward Citations = 1(Granted Patents)

Company Filing History:

8 out of 1,745

Institut National De La Sante Et De La Recherche Medicale

Centre Hospitalier Universitaire De Nantes

5. 1 out of 832,912

Other

patents

where one patent can have more than one assignee

Years Active: 2018-2024

Loading Chart...

9 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12168694 - Anti-human CD45RC antibodies and uses thereof (2024-12-17),

2. 12146159 - Methods for obtaining regulatory t cells and uses thereof (2024-11-19),

3. 12083163 - Isolated interleukin-34 polypeptide for use in preventing transplant rejection and treating autoimmune diseases (2024-09-10),

4. 11090362 - Pharmaceutical composition comprising IL-34 and a mTOR inhibitor (2021-08-17),

5. 10724001 - Methods for obtaining regulatory T cells and uses thereof (2020-07-28),

6. 10591465 - Methods and kits for labeling, detection and isolation of Foxp3regulatory T cells, isolated population of Foxp3regulatory T cells thus obtained and uses thereof (2020-03-17),

7. 10155025 - Method for inhibiting or reducing transplant rejection by adminstration of interleukin-34 (2018-12-18),

8. 10137181 - Isolated donor MHC-derived peptide and uses thereof (2018-11-27),

9. 10105425 - Isolated donor MHC-derived peptide and uses thereof (2018-10-23),

Title: Ignacio Anegon: Innovator in Immunology and Therapeutics

Introduction

Ignacio Anegon, based in Nantes, France, is a prominent inventor recognized for his significant contributions in the field of immunology. With a diverse portfolio containing 9 patents, Anegon's work predominantly focuses on advancing therapeutic options for complex immune-related conditions.

Latest Patents

Among his latest patents, Anegon has developed isolated anti-human CD45RC antibodies. These antibodies and their binding fragments, along with nucleic acids and expression vectors, play a crucial role in treating diseases linked to CD45RC, especially autoimmune disorders, unwanted immune responses, monogenic diseases, and various cancers such as lymphoma. Additionally, his patent involves methods to prevent and treat graft-versus-host disease (GVHD), offering critical insights into therapeutic modalities. Another significant innovation is his method for obtaining regulatory T cells, which outlines a process to cultivate human Tregs from monocytes using interleukin-34, highlighting a groundbreaking approach in immunosuppressive therapies.

Career Highlights

Anegon has had a notable career, working with esteemed institutions such as Inserm (Institut National de la Santé et de la Recherche Médicale) and Université de Nantes. His research has substantially contributed to the understanding and treatment of diseases that affect the immune system.

Collaborations

Throughout his career, Ignacio Anegon has collaborated with talented professionals, including Carole Guillonneau and Severine Bezie. These partnerships have fostered a collaborative environment conducive to innovation and advancements in medical research.

Conclusion

Ignacio Anegon's dedication to his field and impressive array of patents underscore his status as a leading inventor in immunology. His work not only reflects his expertise but also contributes significantly to the ongoing efforts in developing effective therapies for challenging medical conditions.

This text is generated by artificial intelligence and may not be accurate.